NCT00226512View on ClinicalTrials.gov

To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning

PHASE3WithdrawnINTERVENTIONAL

Enrollment

203

Participants

Timeline

Start Date

July 31, 2004

Conditions

Acute Myeloid LeukemiaMyelodysplastic Syndrome

Interventions

DRUG

Campath-1H /ATG

Trial Locations (1)

91120

Hadassah Medical Organization, Jerusalem

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Bayer

INDUSTRY

lead

Hadassah Medical Organization

OTHER